New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
New Red-Blood-Cell-Derived Therapies Are Poised to Launch Rubius into the Spotlight.
Improving Human Health: The Promise of Epigenetics
A New Perspective for Genomic Research from Prof. Shankar Balsubramanian
Translating Innovation into Therapies
Antimicrobial Resistance and Drug Commercialization Were Key Topics at the Recent ON Helix Conference in Cambridge, U.K.
Literature Review: Dielectrophoresis to the Fore
Old Methodology Resurrected to Allow Inexpensive Label-Free Separation of Cell Populations
- Kite Pharma
- 2225 Colorado Avenue
- Santa Monica CA, 90404
- UNITED STATES
Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies for multiple cancer indications. Kite is advancing a portfolio of product candidates designed to leverage and enhance the patient's own immune system to fight tumor cells. These personalized immunotherapies are aimed at providing significant and durable clinical benefit in a wide range of tumor indications.